Using FDA-approved therapies like tirzepatide and semaglutide with close medical supervision, patients achieve meaningful, sustained weight loss and improved metabolic health
Many people notice: Nausea or queasiness, especially early on Constipation or diarrhoea A noticeable drop in appetite, sometimes leading to rapid weight loss For most, these settle as the body adjusts, but the severity varies
Whether it shows up as icy hands, all-day chills, or a sudden drop in body warmth post-injection, the sensation is clearly real - and for some, unsettling
Amgens long-acting monthly obesity therapy MariTide (maridebart cafraglutide, formerly AMG 133) demonstrated substantial and sustained weight loss in a Phase II trial, with patients achieving an average of 20% weight loss without a plateau, along with cardiometabolic improvements, over 52 weeks
In plain terms, semaglutide makes you eat less